On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Objectives
- How do you define ADR?
- How common are ADRs?
- What are the costs of ADRs?
- Benefit-to-risk profile
- Classification of ADRs (1)
- Classification of ADRs (2)
- Pharmacokinetics and pharmacodynamics
- PK-PD Paradigm
- Route of oral medication
- Pharmacology
- Example of a type A ADR (1)
- Schizophrenia
- Dopamine hypothesis
- Correllation between dose-effect
- CNS dopamine pathway
- Dopamine receptors neuroanatomical distributions
- Example of a type A ADR
- Example of a type B ADR
- Mechanism of drug induced toxicity
- Carbamazepine-induced erythema multiforme
- Variability in drug response
- Summary
- Goal of pharmacogenetics
- Pharmacogenetics
- Genotype, phenotype - definitions
- How genotype and phenotype related to each other
- Gene, polymorphism, allele - definitions
- PK-PD paradigm in pharmacogenetics
- Route of psychotrophic drugs
- Polygenic drug response
- Comic relief
- Demographic and environmental factors in ADRs
- Examples of G-E interactions
- Functional polymorphisms in CYP1A2
- PGX methods applied to ADRs
- Central hypotheses
- Genetic association strategy
- Alternative genetic association strategy
- Candidate gene polymorphisms
- Selected examples
- Example of PK polymorphism and ADR
- PGX as applied to debrisoquine
- PGX as applied to succinylcholine
- Example of PD polymorphism and ADR
- PGX as applied to beta-adrenergic agonists
- PGX as applied to quetiapine
- Long QT syndrome mechanism
- Limitations to current strategies
- What are endophenotypes?
- Genotype-endophenotype-phenotype
- Endophenotype of D1 receptor alleles
- Endophenotype of DRD1 Ddel polymorphism
- Other examples and references
- Phase 1 CYP450 polymorphisms and ADRs
- PD polymorphisms and ADRs
- Phase 2 enzyme polymorphisms and ADRs
- Target and transporter polymorphisms and ADRs
- HLA immunoregion polymorphism and ADR
- Possibilities for the furture
- Future directions
- More to come
Topics Covered
- Type A and B Adverse Drug Reactions (ADRs)
- Pharmacokineticpharmacodynamic paradigm
- ADME framework
- Mechanisms of ADRs
- Pharmacogenetics and pharmacogenomics
- Polygenic traits
- Environmental factors
- Phenotype and endophenotype
- Candidate genes
- Association and linkage disequilibrium
Links
Series:
Categories:
Talk Citation
Masellis, M. (2007, October 1). Of genes and drugs: genetic determinants of adverse drug reactions [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 18, 2025, from https://doi.org/10.69645/WPSE4402.Export Citation (RIS)
Publication History
- Published on October 1, 2007
Financial Disclosures
- Dr. Mario Masellis has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Of genes and drugs: genetic determinants of adverse drug reactions
Published on October 1, 2007
41 min